Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its decision to spin out its own candidate into a separate company. In September, Tiziana ...
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company ...
More than half of patients with polymyalgia rheumatica have a relapse during tapering of glucocorticoid therapy. Previous studies have suggested that interleukin-6 blockade may be clinically useful in ...
People with lower interleukin-6 activity have a reduced risk of cardiovascular diseases, a new LMU study reveals. Lowering the activity of interleukin-6 (IL-6) - a key immune signal regulating ...
A pioneering study presented today at ESCMID Global 2025 has uncovered the potential of interleukin-6 (IL-6) as a powerful diagnostic biomarker for the early detection of sepsis in high-risk patient ...
A pioneering study presented today at ESCMID Global 2025 has uncovered the potential of interleukin-6 (IL-6) as a powerful diagnostic biomarker for the early detection of sepsis in high-risk patient ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Among targeted therapies, patients with VEXAS syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results